Cureus meta-analysis compares GLP-1 and SGLT2 ocular outcomes in diabetes
The systematic review pools real-world evidence on eye outcomes in type 2 diabetes patients treated with the two drug classes.
PR
By Priya Raman · Science Reporter
Oct 20 02:17 ETSource: Cureus
The wire
- 01A systematic review and meta-analysis in Cureus compares ocular outcomes between GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes using real-world data.
- 02Retinopathy risk has been a recurring question for prescribers starting incretin therapy, and head-to-head class comparisons inform counselling.
- 03Real-world evidence is subject to confounding by indication and baseline glycaemic control; effect sizes and study inclusion criteria should be checked in the full paper.
From the source
Read at cureus.comOcular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Evidence
